Industry Expert Theater

The Industry Expert Theater brings together industry leaders and attendees interested in the latest drug development research. These hour-long educational (non-accredited) presentations take place in the Oncology Professionals Hall on Saturday, Sunday, and Monday. 

Saturday, June 3

Biosimilar Monoclonal Antibodies: What Oncologists Need to Know
9:30 AM–10:30 AM
Amgen
Presenter:
Richard Markus, VP Biosimilars Global Development, Amgen

 

TECENTRIQ® in Locally Advanced or Metastatic Urothelial Carcinoma (mUC) and Previously Treated Metastatic Non-small Cell Lung Cancer (NSCLC)
12:15 PM–1:15 PM†^
Genentech USA, Inc.
Presenter:
Fairooz Kabbinavar, MD, FACP Principal Medical Director Product Development Oncology, Genentech, Inc.

 

Current Updates in ALK NSCLC and Brigatinib
3:00 PM–4:00 PM†‡
Takeda Oncology
Presenter:
David Kerstein, Senior Director, Clinical Development, Takeda Oncology

 

Sunday, June 4

ZEJULA (Niraparib): A Once-Daily Oral Maintenance Treatment For Recurrent Ovarian Cancer Following Response To Platinum-Based Chemotherapy
9:45 AM–10:45 AM
TESARO
Presenter:
Martin Huber, MD, Senior Vice President, Chief Medical Officer, TESARO

 

Insights in Immuno-Oncology: How Antigens and the Tumor Microenvironment Can Shape the Antitumor Immune Response
11:30 AM–12:30 PM
Amgen
Presenter:
Jackson Egen, PhD, Principal Scientist, Department of Oncology Research, Amgen, Inc.

 

From Evidence to Practice: Biosimilar Trastuzumab and Rituximab
Biosimilar Trastuzumab and Rituximab are not approved in U.S. yet
4:15 PM–5:15 PM
Celltrion Healthcare
Presenters:
Ho Ung Kim, Head of Strategy and Operations Division, Celltrion Healthcare
Hyuk Chan Kwon, MD, Ph.D., Head of Medical Affairs Department, Celltrion Healthcare
Byoung Seo Choi, Head of Marketing Department, Celltrion  Healthcare

 

Monday, June 5

Extending Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma:  Head-to-Head Study Results
9:30 AM - 10:30 AM
Amgen
Presenters:
Amy Kimball MD PhD, Clinical Research Medical Director, Amgen
Andrea Sersch, Executive Medical Director Global Development, Amgen

 

Recent accelerated approval of Bavencio, a checkpoint inhibitor
11:30 AM–12:30 PM
EMD Serono - Pfizer Alliance
Presenters:
Kevin Chin, Vice President –Clinical Development, EMD Serono
Kanwarjit Singh, MD, Team Leader, Oncology Medical Affairs, Pfizer

 

DCVax® - Novel Personalized Immune Therapies for Solid Tumors
3:00 PM - 4:00 PM
Northwest Biotherapeutics
Presenter:
Marnix Bosch, MD, Chief Technical Officer, Northwest Biotherapeutics
 


Only individuals with an attendee designation on their badge will be admitted.
Presentation intended for a U.S. audience only.
^This presentation is intended for US-based HCPs